Last reviewed · How we verify
Vedolizumab SC
Vedolizumab is a monoclonal antibody that selectively blocks the α4β7 integrin on gut-homing lymphocytes, preventing their migration to the gastrointestinal tract.
Vedolizumab SC, developed by Takeda, is a monoclonal antibody targeting gut-specific inflammation. It is currently in Phase 3 and 4 trials for ulcerative colitis and Crohn's disease, with a strong safety profile and promising efficacy. The drug is not yet FDA-approved but has several ongoing and completed trials.
At a glance
| Generic name | Vedolizumab SC |
|---|---|
| Also known as | MLN0002SC, MLN0002, ENTYVIO, KYNTELES, MLN0002, Entyvio, MLN0002, ENTYVIO, KYNTELES |
| Sponsor | Takeda |
| Drug class | Integrin antagonist; monoclonal antibody |
| Target | α4β7 integrin |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
By binding to α4β7 integrin expressed on memory T cells, vedolizumab prevents these cells from adhering to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. This blocks lymphocyte trafficking to the intestinal mucosa, reducing local inflammation in inflammatory bowel disease. The subcutaneous formulation (SC) provides an alternative to intravenous administration with improved patient convenience.
Approved indications
- Ulcerative colitis (induction and maintenance of remission)
- Crohn's disease (induction and maintenance of remission)
Common side effects
- Nasopharyngitis
- Headache
- Arthralgia
- Pyrexia
- Injection site reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vedolizumab SC CI brief — competitive landscape report
- Vedolizumab SC updates RSS · CI watch RSS
- Takeda portfolio CI